BBIO
Income statement / Annual
Last year (2024), BridgeBio Pharma, Inc.'s total revenue was $221.90 M,
an increase of 2,285.27% from the previous year.
In 2024, BridgeBio Pharma, Inc.'s net income was -$535.76 M.
See BridgeBio Pharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$221.90 M |
$9.30 M |
$77.65 M |
$69.72 M |
$8.25 M |
$40.56 M |
$0.00 |
$0.00 |
| Cost of Revenue |
$3.88 M
|
$2.45 M
|
$3.43 M
|
$3.11 M
|
$3.09 M
|
$2.50 M
|
$0.00
|
$260,000.00
|
| Gross Profit |
$218.02 M
|
$6.86 M
|
$74.21 M
|
$66.60 M
|
$5.16 M
|
$38.06 M
|
$0.00
|
-$260,000.00
|
| Gross Profit Ratio |
0.98
|
0.74
|
0.96
|
0.96
|
0.63
|
0.94
|
0
|
0
|
| Research and Development Expenses |
$506.46 M
|
$455.71 M
|
$402.90 M
|
$454.14 M
|
$337.05 M
|
$209.95 M
|
$140.07 M
|
$30.56 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$145.68 M
|
$94.35 M
|
$43.59 M
|
$13.30 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$288.93 M
|
$150.59 M
|
$143.19 M
|
$192.21 M
|
$145.68 M
|
$94.35 M
|
$43.59 M
|
$13.30 M
|
| Other Expenses |
$15.61 M
|
$7.93 M
|
$100.45 M
|
$35.82 M
|
$1.63 M
|
-$1.21 M
|
-$1.29 M
|
$0.00
|
| Operating Expenses |
$811.00 M
|
$614.23 M
|
$546.09 M
|
$646.35 M
|
$482.73 M
|
$304.30 M
|
$183.66 M
|
$43.86 M
|
| Cost And Expenses |
$814.88 M
|
$616.67 M
|
$546.09 M
|
$646.35 M
|
$482.73 M
|
$306.80 M
|
$183.66 M
|
$43.86 M
|
| Interest Income |
$17.25 M
|
$18.04 M
|
$7.54 M
|
$1.13 M
|
$4.02 M
|
$8.92 M
|
$2.00 M
|
$39,000.00
|
| Interest Expense |
$99.29 M
|
$81.29 M
|
$80.44 M
|
$46.78 M
|
$36.66 M
|
$8.77 M
|
$2.55 M
|
$13,000.00
|
| Depreciation & Amortization |
$6.08 M
|
$6.49 M
|
$6.77 M
|
$5.84 M
|
$3.09 M
|
$859,001.00
|
$245,000.00
|
$260,000.00
|
| EBITDA |
-$436.83 M |
-$565.47 M |
-$397.44 M |
-$533.83 M |
-$465.75 M |
-$279.82 M |
-$183.42 M |
-$43.56 M |
| EBITDA Ratio |
-1.97
|
-60.78
|
-4.55
|
-7.74
|
-56.84
|
-6.89
|
0
|
0
|
| Operating Income Ratio |
-2.67
|
-65.29
|
-6.08
|
-8.32
|
-57.52
|
-6.56
|
0
|
0
|
| Total Other Income/Expenses Net |
$50.78 M
|
-$45.88 M
|
$27.55 M
|
-$9.82 M
|
-$31.01 M
|
-$22.35 M
|
$14.21 M
|
$26,000.00
|
| Income Before Tax |
-$542.19 M
|
-$653.25 M
|
-$484.65 M
|
-$586.45 M
|
-$505.49 M
|
-$288.59 M
|
-$169.45 M
|
-$43.83 M
|
| Income Before Tax Ratio |
-2.44
|
-70.22
|
-6.24
|
-8.41
|
-61.28
|
-7.12
|
0
|
0
|
| Income Tax Expense |
$1.15 M
|
$0.00
|
$9.31 M
|
$52.84 M
|
-$21.56 M
|
-$28.15 M
|
$16.76 M
|
-$13.49 M
|
| Net Income |
-$535.76 M
|
-$643.20 M
|
-$493.96 M
|
-$639.30 M
|
-$483.93 M
|
-$260.44 M
|
-$130.75 M
|
-$30.57 M
|
| Net Income Ratio |
-2.41
|
-69.14
|
-6.36
|
-9.17
|
-58.66
|
-6.42
|
0
|
0
|
| EPS |
-2.88 |
-3.95 |
-3.35 |
-4.43 |
-4.1 |
-2.48 |
-1.42 |
-0.33 |
| EPS Diluted |
-2.88 |
-3.95 |
-3.35 |
-4.43 |
-4.1 |
-2.48 |
-1.42 |
-0.33 |
| Weighted Average Shares Out |
$186.08 M
|
$162.79 M
|
$147.47 M
|
$144.36 M
|
$118.00 M
|
$105.10 M
|
$92.33 M
|
$92.33 M
|
| Weighted Average Shares Out Diluted |
$186.08 M
|
$162.79 M
|
$147.47 M
|
$144.36 M
|
$118.00 M
|
$105.10 M
|
$92.33 M
|
$92.33 M
|
| Link |
|
|
|
|
|
|
|
|
